Patents by Inventor Elyssa B. Margolis

Elyssa B. Margolis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of determining delta opioid receptor subtypes
    Patent number: 8691768
    Abstract: The present invention provides methods of treating or preventing a substance-related disorder using selective delta opioid receptor-1 (DOP-R1) agonists, delta opioid receptor-2 (DOP-R2) antagonists, and/or mu opioid receptor (MOP-R) antagonists, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist. The methods also comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and an MOP-R antagonist. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist and a MOP-R antagonist. The invention also relates to compositions containing the same. The invention also relates to methods of determining delta opioid receptor specificity of candidate agents.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: April 8, 2014
    Assignee: The Regents of the University of California
    Inventors: Howard L. Fields, Jennifer M. Mitchell, Elyssa B. Margolis
  • METHODS AND COMPOSITIONS USING SELECTIVE DELTA OPIOID RECEPTOR-1 AGONISTS, DELTA OPIOID RECEPTOR-2 ANTAGONISTS, AND/OR MU OPIOID RECEPTOR ANTAGONISTS FOR TREATMENT OF SUBSTANCE-RELATED DISORDERS
    Publication number: 20110046064
    Abstract: The present invention provides methods of treating or preventing a substance-related disorder using selective delta opioid receptor-1 (DOP-R1) agonists, delta opioid receptor-2 (DOP-R2) antagonists, and/or mu opioid receptor (MOP-R) antagonists, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist. The methods also comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and an MOP-R antagonist. The methods provided herein further comprise administering a therapeutically effective amount of a combination of a DOP-R1 agonist and a DOP-R2 antagonist and a MOP-R antagonist. The invention also relates to compositions containing the same. The invention also relates to methods of determining delta opioid receptor specificity of candidate agents.
    Type: Application
    Filed: May 1, 2009
    Publication date: February 24, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Howard L. Fields, Jennifer L. Whistler, Jennifer M. Mitchell, Elyssa B. Margolis, Richard M. van Rijn